Article Text
PostScript
Letter
Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease
Statistics from Altmetric.com
Footnotes
Competing interests Dr Lewis has had research support from Centocor, Shire, and Takeda. He has served as a consultant for GlaxoSmithKline, Centocor, Novartis, Shire, Millenium Pharmaceuticals, Elan, Proctor & Gamble, and Astra Zeneca.
Provenance and peer review Not commissioned; externally peer reviewed.